news
Novartis drug Afinitor® recommended by FDA oncology advisory committee
12 April 2011 | By Novartis
Novartis announced that the FDA Oncologic Drugs Advisory Committee recommended approval of Afinitor® (everolimus) tablets...
List view / Grid view
Novartis
news
Social media and the pharma industry
11 April 2011 | By GDS International
Every other industry is getting on the social media bandwagon. But could social media actually prove beneficial to the world of pharma?...
news
Novartis shareholders approve merger of Alcon into Novartis
8 April 2011 | By Novartis
Novartis shareholders followed the Board of Directors' recommendation, approving the proposed merger of Alcon, Inc. into Novartis...
news
Novartis first-in-class antiviral DEB025 achieved sustained viral response
31 March 2011 | By Novartis
Novartis announced that a Phase II study with the first-in-class antiviral DEB025 met its primary endpoint for achieving viral cure...
news
Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China
22 March 2011 | By Novartis
Novartis announced that it completed the transaction to acquire an 85 percent stake in Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd...
news
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment
21 March 2011 | By Novartis
The European Commission has granted Novartis approval for Gilenya®...
news
Novartis appoints Naomi Kelman as new Head of the Novartis OTC division
17 February 2011 | By Novartis
Novartis announced that effective March 2, Naomi Kelman is appointed Head of the Novartis OTC Division...
news
Novartis studies show Onbrez® Breezhaler® & tiotropium provided greater increase in lung function than tiotropium alone
10 February 2011 | By Novartis
Patients with COPD treated with Onbrez® Breezhaler® & tiotropium notice improvements...
news
Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET
9 February 2011 | By Novartis
NEJM published a study that shows Afinitor® tablets plus BSC more than doubled PFS...
news
FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo®
31 January 2011 | By Novartis
The FDA approval of Menveo for use in children 2 to 10 years of age is based on Phase III trial data involving 5,297 participants in that age group...
news
Novartis announces agreement to acquire Genoptix, Inc. in all cash offer
24 January 2011 | By Novartis
Novartis announced today that it has entered into a definitive agreement for the acquisition of Genoptix, Inc...
news
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
24 January 2011 | By Novartis
Swissmedic and TGA have granted approval for Gilenya® (fingolimod)...
news
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Glivec® in slowing disease progression in patients
6 December 2010 | By Novartis
with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)...
news
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment
17 November 2010 | By Novartis
Novartis presented a strategic overview of the company's diversified healthcare portfolio which creates potential for future sustainable growth...
article
Indirect modulation of cardiac ion channels and implications for preclinical safety assessment
19 August 2010 | By Gül Erdemli & Dmitri Mikhailov, Center for Proteomic Chemistry, Novartis Institutes for BioMedical Sciences and Albert M Kim, Translational Medicine, Novartis Institutes for BioMedical Sciences
The preclinical assessment of a small molecule’s liability for QT interval prolongation is an essential part of the drug discovery process. Patch clamp assays for heterologously expressed recombinant cardiac ion channels are widely used in the pharmaceutical industry to evaluate potential drug-channel interactions. These assays are generally acute assessments and…
